Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

May 10, 2022

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 57 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thanks for holding. You're joining Bayer's Investor and Analyst Conference Call covering the Q1 2022 Results. During this recorded presentation today, everyone will be in listen-only mode. After the presentation, we'll open it up for a question and answer session. Should anyone have trouble hearing the conference, just press the star key and then zero on your phone and the operator will assist you. At this point, I'll hand things over to Mr. Oliver Maier, Head of Investor Relations at Bayer AG. Sir, the floor is yours.

Oliver Maier

executive
#2

Thanks, Stuart. Good afternoon, everyone, and thank you for being with us today. I want to welcome each of you to our Q1 2022 conference call. Joining me on the call are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO. The businesses are represented by the responsible management board members. As usual, Werner will kick off today's call with a review of the key developments in the Q1. After that, Wolfgang will go through how our business performed and the outlook for 2022, and then we'll open the Q&A session. Before we get started today, I'd like to point out the cautionary language contained in our safe harbor statement and in all the materials we've distributed today. With that, Werner, over to you.

Werner Baumann

executive
#3

Thanks, Oliver, and good afternoon, everyone. I'm glad to have you with us on the call for Q1. Before we get into how the business performed, I want to begin by addressing the Russian invasion of Ukraine — what it means and how our company is responding. With the war in Ukraine, meeting our social and humanitarian duty ranks among our highest priorities. We keep working to make sure life-saving medicines and agricultural products reach the civilian population. At the Ukrainian government's request, we have donated medical products as well as seed products. Antibiotics for 27,000 people in Ukraine have been delivered. Right now, we are giving more than 1,000 smallholder farmers in Ukraine 41,000 bags of corn seed at no cost, which should hopefully add roughly 180,000 metric tons to the corn harvest. We have also made monetary contributions to aid organizations and helped refugees find shelter. The consequences of the Russian invasion into Ukraine reach much further. Both countries are major players in global food supply, particularly for the world's poorest regions. Food security is already under enormous threat, especially in the Middle East and Africa, and food prices are rising.

Werner Baumann

executive
#4

When it comes to agricultural products, we're a global leader, and at this moment we're focused on locking in supply of what we make, helping keep worldwide ag supply chains running, and expanding on the growing access we have to smallholder farmers. Over a longer horizon, the strength of our innovation will help agriculture become more productive and more sustainable, safeguarding the world's food supply while using fewer resources. All of this demonstrates that these days Bayer carries systemic relevance and a distinctive responsibility when it comes to human health and nutrition — more so than ever before. Now let me walk you through a quick update on where things stand with litigation. On the glyphosate front, we're continuing to carry out our five-point plan. As you're aware, the U.S. Supreme Court requested that the Solicitor General, on behalf of the U.S. government, submit a brief in the Hardeman case, and that is what we're awaiting. Whatever the final Supreme Court ruling turns out to be, we're ready for it. Turning to the PCB water litigation, the U.S. District Court for the Central District of California lately gave preliminary approval to the settlement agreements that we announced in June 2020 with the class of municipal entities. We've additionally struck agreements that resolve cases with the attorneys general of a number of U.S. states, yet trials are still slated in the coming weeks — in both personal injury and environmental cases, including one that involves the state of Oregon.

Werner Baumann

executive
#5

Now let's turn to how operations performed during Q1. The year has gotten off to a highly successful start, with outstanding increases in both sales and earnings, thanks in particular to favorable market conditions for our Crop Science business. Beyond that, Consumer Health kept up its broad-based growth path, fueled by robust demand in nutritionals along with a rebound in growth rates within the allergy and cold category. Volumes in our Pharmaceuticals business kept climbing as well, most notably for Eylea, our blockbuster. Our launch products likewise carried on performing strongly. That leads me into an innovation update. We advanced our innovation agenda with several important strides. For Kerendia, approval has been secured for treating adults who have chronic kidney disease together with type 2 diabetes in the EU and Japan. For NUBEQA, we filed applications for additional indications covering patients with metastatic hormone-sensitive prostate cancer in the U.S., the EU, Japan, and China, and we were delighted that the U.S. FDA granted priority review last week. Through the submissions for this label extension, we have already checked off one of our key pipeline catalysts for this year. In early April, we additionally presented positive results from the first phase IIb trial examining the safety of Asundexian in patients with atrial fibrillation.

Werner Baumann

executive
#6

Later in the year, we intend to make a decision regarding phase III for the Factor XI program, and we anticipate phase III results for the 8 mg dose of Eylea, along with the interim analysis from our BlueRock phase I Parkinson's program, BRT-DA01. As we look forward, there are certainly some macro variables for the rest of the year. The COVID pandemic has already caused global supply chains to be stretched, and now we are seeing added pressure stemming from the war in Ukraine. Like most other companies, energy security is one of our key areas of focus, both for our own operations and within our supply chain. We are working intensively on supply security for our production sites and are developing various scenarios and action plans in case of reduced gas availability and possible disruptions at the supplier level. On the cost side, we keep seeing substantial increases in materials and services, which is a theme common across countries and industries. As we outlined in our full year guidance and on the conference call, we are offsetting these effects through ongoing cost and pricing management. Regarding the macro variables, we will certainly have a clearer picture as the year goes on, and we will keep you updated accordingly.

Werner Baumann

executive
#7

To sum up, let me stress once more that the year got off to a really strong beginning, and we feel positive about all of 2022 as well. The climate around us, naturally, remains rather unstable. As things look right now, we have strong confidence that our ambitions for the entire year will be met. With that, Wolfgang, I'll turn things over to you for further specifics on how our business performed and the assumptions underpinning our outlook.

Wolfgang Nickl

executive
#8

Okay. Thanks, Werner. Good morning, everyone. I'll take you through how the business performed in Q1 and then share our financial outlook for the whole of 2022. During Q1, group sales rose substantially — up 14% on a currency- and portfolio-adjusted basis — reaching EUR 14.6 billion. Crop Science stood out as the largest driver. Group EBITDA before special items came to EUR 5.3 billion, a 28% year-over-year gain. The EBITDA margin before special items finished 250 basis points higher than a year earlier, at 35.9%. Let me touch briefly on the FX effects we observed during the quarter. Sales carried a meaningful tailwind of EUR 529 million, while the effect on EBITDA was smaller, at EUR 67 million. The key driver is appreciation of currencies in countries where our cost base is comparatively larger, such as the U.S., versus depreciation of currencies in countries where that base is smaller, such as Turkey. Although positive in absolute terms, that produces 90 basis points of margin dilution. You'll notice these effects in the divisional results as well, though the size varies depending on each business's footprint and FX exposure. Core earnings per share in Q1 were EUR 3.53, an increase of EUR 0.94 versus the prior year, powered by strong performances at Crop Science and Consumer Health.

Wolfgang Nickl

executive
#9

The underlying financial figure stayed about where it was a year earlier — EUR 419 million against EUR 385 million in the prior year. Our core tax rate was 22.1%, compared with 24.3% in Q1 of last year, thanks to one-time benefits from revaluing deferred taxes in the United States. For the full year, we still anticipate a core tax rate of roughly 23%, in line with guidance. Free cash flow for Q1 of 2022 came to -EUR 1.2 billion, versus -EUR 3.2 billion in 2021. That improvement stems mainly from smaller settlement payments for glyphosate and Assure — EUR 470 million in Q1 this year, against EUR 2.2 billion last year. Higher top line, especially from our Crop Science business, produced the associated build-up in accounts receivable, which will be collected over the coming quarters. As a result, and as expected, net financial debt rose to EUR 34.5 billion in Q1, reflecting free cash flow seasonality and the strength of the US dollar. Let's now turn to how our three businesses performed. Our crop division delivered an outstanding Q1, with sales of EUR 8.4 billion. That amounts to currency and portfolio adjusted sales growth of 22%.

Wolfgang Nickl

executive
#10

Roughly 75% of that increase stems from price, while about 25% comes from greater volumes. Looking at the segments specifically, herbicides made up the biggest single contribution, posting 60% growth on a currency- and portfolio-adjusted basis. Strong pricing for our glyphosate-based products drove around 75% of that gain, with volume expansion accounting for most of what remained. Our corn seeds and traits franchise rose 10% on a currency- and portfolio-adjusted basis, growing across every region, largely because of price. Volumes also rose, with the exception of North America, where planted acres are expected to decline. Soybean seeds and traits sales matched the prior year, at +1% currency and portfolio adjusted. In North America, we achieved stronger pricing as additional growers keep upgrading to our newest XtendFlex soybeans. That gain, though, was offset by lower volume in Latin America after the previously announced discontinuation of our Argentine soy business, which had only a minor impact on our bottom line. Our fungicides business grew 19%, driven mainly by higher volumes across every region. In particular, we saw early demand as growers look to lock in supply amid uncertain times. On profitability, the considerable pricing gains in herbicides and in corn and soy produced an all-time high margin of 43.4%, up 660 basis points year-over-year.

Wolfgang Nickl

executive
#11

EBITDA before special items rose 50% to EUR 3.7 billion, and better pricing plus efficiency actions more than offset roughly EUR 200 million of cost inflation in the Q1. Year-over-year, foreign exchange effects produced a tailwind of EUR 98 million. At our pharma division, sales adjusted for currency and portfolio grew 3%, primarily on continued volume expansion. Eylea, our blockbuster drug, kept up its strong trajectory, posting 14% growth on a currency and portfolio adjusted basis, and it is especially picking up market share in growing markets such as Europe and China. On top of that, the ongoing launch of Eylea pre-filled syringes and the recovery from COVID-19 restrictions contributed to top line growth. Across pharma as a whole, we observe a slightly negative price trend of -1% year-over-year, driven in particular by price reductions from volume-based procurement for Xarelto in China. On a currency and portfolio adjusted basis, that resulted in a 5% decline in total Xarelto sales in the Q1. NUBEQA, our new prostate cancer drug, maintained strong rollout momentum and reached sales of EUR 76 million. Sales in the Q1 were driven by new patient starts and market share gains in the approved non-metastatic prostate cancer indication, and we are already getting ready for the launch in the metastatic cancer setting.

Wolfgang Nickl

executive
#12

For the first quarter, our top line was also helped by radiology, which kept delivering strong results and carried on bouncing back from the COVID-19 restrictions we saw a year earlier. Turning to the bottom line, EBITDA before special items in pharma came in 7% lower at EUR 1.4 billion, a margin of 30% versus 34.3% in Q1 of 2021. The main reasons behind that move were our sustained spending on innovation and future growth — in particular the Kerendia launch and the continuing rollout of NUBEQA and Verquvo. On top of that, we had higher R&D expenses tied to terminated pipeline projects, along with the non-recurring EUR 52 million in proceeds from Q1 2021 related to selling a priority review voucher. Given how our pharma business is set up regionally and its foreign exchange exposure, FX movements created a EUR 34 million headwind, or 160 basis points of margin dilution year-on-year, mostly from the US dollar. We finish the divisional updates with consumer health. Sales rose 17% there on a currency and portfolio adjusted basis, growing across regions and categories as we cycled a soft quarter a year ago. Our allergy and cold category rebounded 39% after demand for cough and cold products was very low in Q1 of last year because of COVID-19 restrictions.

Wolfgang Nickl

executive
#13

Nutritionals kept up its robust upward path, supported by broader preventive-health trends, and delivered 15% growth. The Bepanthen Dry Skin line extension helped dermatology post 12% growth. We also saw some demand pulled into Q1, partly because shoppers were buying ahead of price increases across categories and partly because of COVID-19-related worries about future supply. EBITDA before special items for Consumer Health rose 33% to EUR 388 million, and the margin expanded substantially by 240 basis points to 25.7%. Strong top-line growth, ongoing spending discipline, and price management were able to offset inflationary cost pressures. Q1 also included divestment income from the sale of a small non-strategic brand. Year-over-year foreign exchange effects produced a slight tailwind in earnings but a 30 basis point dilution of margin. Let's turn now to our guidance for the full year. As Werner already noted, we have a strong start, with very good growth and earnings progression, and we feel optimistic about the year. Even so, plenty of uncertainty and volatility lie ahead that we'll have to manage, whether that's the Ukraine war, COVID-19, or the supply and energy-related challenges we may encounter. Given that backdrop, we are maintaining our full year operational guidance at this point in time, and we'll review it once we have more visibility.

Wolfgang Nickl

executive
#14

So today's update really only concerns exchange rates. Over in the light blue column on the right-hand side, you'll find our newest estimate of how currency is affecting things, and that's built on month-end rates for March 2022 compared with the constant currency scenario. One more thing to keep in mind: our guidance on a currency-adjusted basis continues to assume that the environmental science professional business will be divested by mid-year as a going concern. With that said, Oliver, I'll turn things back to you so we can kick off the Q&A.

Oliver Maier

executive
#15

Okay, thanks a lot, Wolfgang. And thank you, Werner, for walking us through that. I believe, Stuart, we can jump straight into the Q&A now and get the lines opened up.

Operator

operator
#16

Thanks, Oliver. Ladies and gentlemen, we're going to start the question-and-answer portion right now. Should you have a question, kindly press the star key and then the number one on your phone. To withdraw your request, press star and then the number two. Should you be on speaker equipment today, please pick up the handset before you make your selections. Please hold a moment for the first question. Our first question comes from Vincent Andrews at Morgan Stanley. Please go ahead.

Vincent Andrews

analyst
#17

Thanks, and good morning, everyone. Rodrigo, if I may, clearly glyphosate pricing stood out as a major factor, as expected, the last time we talked. During the Q4 results, you mentioned expecting likely some price correction in the back half as supply gets better, and supply out of China was going to be the major uncertainty. Can you update us on what you're observing regarding competitors' output, and what you expect for the path of glyphosate pricing in the back half of the year?

Rodrigo Santos

executive
#18

Thanks, Vincent. Yeah, you're spot on about what we discussed regarding the guidance. Glyphosate accounts for 50% of the growth we saw in Q1. Within our herbicide business, 75% comes from glyphosate. As we anticipated, Q2 still shows a solid price, though in the back half of the year we expect things to normalize, correct? Inventory is rising in China. That's what our plan assumes. Naturally, we stand ready to seize any opportunity that arises, depending on how we track it. Our plans remain in place across the market, and hopefully we can grab additional opportunities in the second half, but we're planning for prices to normalize more in the back half of the year.

Vincent Andrews

analyst
#19

Alright, as a follow-up, regarding the seed business in South America for the second half of the year too — and I suppose especially in Brazil, where the currency has moved quite a bit — have you already set seed prices for the second half consistent with the sort of expectations you gave us earlier, or has anything shifted in your pricing expectations for Lat Am in seed for the second half?

Rodrigo Santos

executive
#20

No, the pricing is already set, Vincent, and it matches what we laid out here. To give everyone else the picture, our plan for this year involves roughly a 6%-7% price increase across our corn businesses and our fungicides and insecticides, and that is what we're carrying out in the market.

Vincent Andrews

analyst
#21

All right, thank you so much.

Rodrigo Santos

executive
#22

I appreciate that.

Operator

operator
#23

Our next question comes from Pete Verdult at Citigroup. Please go ahead.

Peter Verdult

analyst
#24

Pete from Citigroup here. I have two questions. First, Werner and Wolfgang, you've basically hit most of the 2022 guidance in Q1 by yourselves. You've said some things about feeling very optimistic regarding meeting guidance. Is the absence of any change just because it's so early in the year and you're being abundantly cautious, or have you noticed any troubling signals when it comes to volume and price trends in Q2? The second question is for Stefan about asundexian. I understand you can't get into specifics or speak quantitatively about the PACIFIC-Stroke and PACIFIC-AMI data you have in-house, but just following on from and building upon the AF data we all saw at ACC, could you offer any qualitative remarks on your enthusiasm for the program and how that has shifted, and how your phase III ambitions may have been shaped as you see more data? Thank you.

Werner Baumann

executive
#25

Okay, Pete. Morning. Before passing things to Stefan, I’ll take the guidance and Q1 question. To put it briefly, Q1 was obviously very, very strong, and you’re right to note that a fair amount of this year’s earnings progression has already come through in Q1. That was planned as well. Yeah, we told you the first half would be very, very strong under the assumptions we made, especially in crop, with a first half that would include strong glyphosate pricing, including the points Rodrigo just mentioned. For our planning, we assumed a normalization in the second half. Needless to say, if those assumptions prove conservative, there would be upside. At the same time, you’ve heard this from me and also from Wolfgang: we’re seeing quite a bit of volatility out there. So for now we’ve chosen to keep the guidance that’s out there, and we’ll review it as we go further into the year.

Werner Baumann

executive
#26

I'll pass things over now to Stefan.

Stefan Oelrich

executive
#27

Hi, Pete. Thanks for asking. Naturally, the results from PACIFIC-AF have us excited. As a quick reminder for everybody, a two-thirds reduction in bleeding is something we clearly feel very, very good about. And then there's what we've observed in terms of mode of action — the potent inhibition of factor XIa activity, which exceeds 90% at the high dose and falls in the 80%-90% range at the low dose in our dosing studies. You're right. Or, I suppose, as you know, efficacy can't be concluded from that. In AF patients today, bleeding ranks as one of the most important side effects — perhaps the most important side effect physicians see. We consider this very significant. I'll leave it there. Right now we're analyzing the stroke and AMI data in-house. We're crunching the numbers as we speak. We'll be presenting this

Werner Baumann

executive
#28

Once we get to a scientific meeting later in the summer, we'll have a clear picture of how we plan to move the phase III program forward.

Sachin Jain

analyst
#29

I appreciate that.

Operator

operator
#30

Our next question comes from Sachin Jain at Bank of America. You have the floor.

Sachin Jain

analyst
#31

Sachin Jain from Bank of America here. I have two topics, and both are really just clarifications on earlier points. Werner, regarding the macro factors and the volatility you mentioned, I just want a little more color — I'm checking whether, if the current macro factors persist, we should treat the guidance as conservative and assume macro conditions would need to deteriorate for an upgrade to guidance later in the year. Just to clarify that volatility reference. Then Stefan, apologies for following up further on asundexian, if I may. First, how are you thinking about whether to make a phase III decision by partnering this asset rather than advancing it alone? You also mentioned making a phase III decision toward the back end of the year. I want to be super clear on this. The NEJM paper on PACIFIC-AF essentially said a phase III in SPAF was warranted. Is the debate you're having about whether you go broader than SPAF into non-embolic stroke ACS, which is the data you have in-house, or is SPAF still under debate? Thank you.

Werner Baumann

executive
#32

I'll begin once more with the opening question before passing things back to Stefan. Regarding the macro picture, what we observed in Q1 — if that were to hold steady, it would naturally give us some upside. Right, we haven't encountered any ceiling on our capacity to handle that kind of turbulence during Q1. You've watched us move decisively on price. Rodrigo mentioned that earlier, and it shows up as well in the figures we reported. We've dealt with the supply chain strain across our businesses quite effectively. We're running our product supply organization. Our people go to extraordinary lengths — they jump through fire rings — to produce what we're able to sell, since demand is genuinely extremely strong. What I said, and what Wolfgang said too, had to do with the volatility out there, given that we don't know what will actually happen. If conditions stay comparatively calm, as they are at present, I believe matters would in fact be extremely good. Out of caution, because we don't know what the coming month will bring, we've kept the guidance unchanged, and let me just restate what Wolfgang said, for the time being.

Stefan Oelrich

executive
#33

Hi, Sachin. And again on asundexian, the question of whether we can go beyond AFib is exactly what we're examining at this moment, drawing on the other two studies. It's a very broad program of studies that we ran in terms of the patients we enrolled. There's a lot of data to review in both stroke and PACIFIC-AMI. Yes, as I said, the results from the AFib trial encourage us, and we see ourselves as phase III ready for decision-making in the second half. On partnering, you know, we hold full global rights to asundexian. It belongs to us. We've been building a U.S. footprint for the Verquvo launch, and we're also supporting Merck with their Verquvo launch in the U.S. We have a solid presence that we can build on. To date we have made no determination about whether to partner or not, but obviously that remains an option for us. We also feel strong enough, if need be, to go it alone.

Sachin Jain

analyst
#34

Thanks — that’s very clear.

Operator

operator
#35

The following question comes from Michael Leuchten at UBS. You have the floor.

Michael Leuchten

analyst
#36

Thanks so much. I have two questions, please. The first is for Rodrigo. If we return to the start of the year, when you stated quite clearly that this year's guidance rested mainly on price — now you delivered volume growth of almost 6% in Q1. Did that come in ahead of what you expected, or was the volume contribution consistent with how you anticipated the year unfolding? Then a question for Stefan. It feels like it has been some time since we saw pipeline pruning in pharma at Bayer. I'm curious whether you could address the timing of those discontinuations and the decisions behind them, and also what the underlying pharma EBITDA margin would have been in Q1 absent the R&D charge for the quarter. Thank you.

Werner Baumann

executive
#37

Thank you. I appreciate the question. I'll begin with Crop Science. Of the growth we achieved, 75% came from pricing while 25% was volume-driven. It's encouraging that we're seeing certain volume gains, particularly in corn, as Wolfgang noted — that was true nearly everywhere except the US, where acreage declined and, more specifically, there's been a shift toward soybean. We also observed a degree of pull-forward in volume for the fungicide, just to give one example. That was somewhat visible, which explains why we still expect some growth in Q2, though likely about half of what Q1 delivered. That's roughly how our plan looks, and then Q2 and the second half of the year unfold as we described. For the full year, I'd say pricing will provide the largest share of the growth we generate in the Crop Science division. I'm pleased with how execution and discipline are showing up across every market and every business line on that front. With that, I'll hand things over to Stefan.

Stefan Oelrich

executive
#38

Thanks, Michael. Having bad data from clinical research is never desirable. Thankfully, we've had very little of that recently. The impact on Q1 is fairly limited. When you look at our margin, currency headwinds have been the main factor we've been facing. On the positive side, we also had the PRV last year in Q1, which we don't have this quarter. Pipeline effects are relatively minor. We should be at our target margin for the year.

James Quigley

analyst
#39

Thanks.

Operator

operator
#40

Our next question comes from James Quigley of Morgan Stanley. Please go ahead.

James Quigley

analyst
#41

Hello, and thank you for taking my questions. I have a couple of product-related questions and one about provisions. NUBEQA received fast track designation in the metastatic setting. What feedback have you received on the ARASENS trial data so far? And given that feedback, how are you viewing the launch pace? Also, which key areas or issues do you need to address with potential prescribers regarding the use of chemo in combination with NUBEQA? Turning to the broader Factor XI portfolio, Osozumab and Fisomersen, the trials in end-stage renal disease were completed per clinicaltrials.gov either late last year or early this year. What is the latest on these two assets? When might we potentially see some data? Are there any particular advantages to using the antibody or mRNA approaches, or RNA approaches, in end-stage renal disease? Just a clarification on potential data timing for asundexian. You mentioned a medical conference after the summer, and ESC falls right at the end of the summer. Do you expect to miss ESC, or could you potentially be at ESC? A very quick final one on provisions. Regarding the glyphosate provision at the end of last year, you said $7.5 billion remained, and you will be paying out EUR 2.5 billion in provisions this year.

James Quigley

analyst
#42

How much of that EUR 2.5 billion is tied to the glyphosate liability, just so we have a sense of where the provision might stand by year-end? Thank you.

Stefan Oelrich

executive
#43

All right, thank you, James. That was a fair number of questions, so I hope I managed to address everything you raised. The audio wasn't great. If anything's missing, please go ahead and ask more questions to round out my response. Regarding NUBEQA, on your question about how regulators are responding to the ARAMIS trial — clearly favorable, since the FDA granted us a priority review. We ought to receive clearance to market it in the United States very shortly. What we hear from the KOL community regarding ARAMIS has been overwhelmingly positive and encouraging, because we now essentially span both ends of prostate cancer, from the non-metastatic castrate-resistant patient through to the metastatic patient who is also receiving chemo. From a data standpoint it's very encouraging, and in oncology that's what matters. We think this will give a further lift to the positive launch momentum NUBEQA already has. Factor XI. That's a really good question you posed. When does summer finish? Let's say summer wraps up at some point during July and August in our part of the world. That could take in a congress in Europe. I think — or rather, let's say summer concludes before that, and it will fall at a congress from then on.

Stefan Oelrich

executive
#44

The name of that scientific meeting isn’t something I’m permitted to share. Yeah, part of what you asked about asundexian—other aspects of it—I wasn’t able to hear clearly. Could you please ask that again? I couldn’t.

James Quigley

analyst
#45

It was really just a status update on the Factor XI antibody as well as the RNA therapy.

Stefan Oelrich

executive
#46

Oh.

James Quigley

analyst
#47

What kind of timeline might we have for seeing data on those 2?

Stefan Oelrich

executive
#48

Yeah, it's very much like asundexian. We're working our way through the data, and we expect to make a decision in the second half about what we do with all 3 of them. You know, we've got an antibody, an antisense, and an oral, and we'll go from there.

James Quigley

analyst
#49

Thanks.

Wolfgang Nickl

executive
#50

Yes. James, I’ll address the provision question. As you might remember, at year-end we had roughly EUR 9 billion in total on the books for provisions tied to legal cases. You saw us pay out around half a billion EUR in Q1. Just to remind everyone, these aren’t new settlements. They’re simply.

James Quigley

analyst
#51

All right.

Wolfgang Nickl

executive
#52

Those settlements we finalized in the prior year are now reaching the payout stage. That puts us at roughly EUR 8.5. Broadly speaking, this covers glyphosate, naturally, along with PCB and a modest amount of Essure and dicamba. Still, you can assume glyphosate accounts for the lion's share. Figure roughly 80% of it. You heard that

Rodrigo Santos

executive
#53

We just received preliminary approval on the PCB for the class settlement. You can take it that after that is finalized, there will also be payouts from it. It remains our assumption, based on the pre-agreements we had for the year, that we'll have a total in our cash flow and in our net debt forecast of roughly EUR 2.5 billion. Some of that is to come for the rest of the year.

Werner Baumann

executive
#54

Thanks a lot. Appreciate it.

Rodrigo Santos

executive
#55

No problem at all.

Operator

operator
#56

Our following question comes from Keyur Parekh at Goldman Sachs. The line is yours.

Keyur Parekh

analyst
#57

Hello, and thanks for taking my questions — I have two, if I may. First, given the growth in crop and the roughly 11% growth you expect for the crop business in Q2, I'm wondering how much glyphosate pricing has to fall in the second half of the year for you to hit that 7% guidance for the full year. Because by my math, glyphosate pricing would need to be down north of 25% for that to be realistic. So I'm just wondering whether that math is in fact correct, and whether you have visibility into the reopening of Chinese production there. That's my first question. Second, I'm wondering whether you can give any update on the situation with SCOTUS. I know nothing is publicly available, but just how confident are you that you'll hear back from the Solicitor General during the middle of 2022? Thank you.

Rodrigo Santos

executive
#58

Thanks for the question. I'll begin with glyphosate pricing and the plan we have in place. When we provide guidance — and Vincent mentioned this at the start of the call — when we guide for the year, our plan assumed a very strong first six months followed by a weaker second half. That was part of the plan. By the way, in line with that, the execution we're doing is probably a little bit better than that. What we planned for, and again, having worked 25 years in this industry and with glyphosate, we've seen those scenarios before, right? What we planned for the second half is more a normal glyphosate price compared with the historical level, plus some additional costs that affected the entire industry. That's what's in the plan. As Werner referred to, we're going to keep executing. Hopefully we can do better than that, but that was the plan we put in place for the second half of the year. With that, I'll hand it to you, Werner, on the second part of the question.

Werner Baumann

executive
#59

Yeah, thanks, Rudy. All right. Regarding SCOTUS, the Solicitor General delivering the government's opinion has no time constraint attached. There isn't any deadline we can, you know, pin down, so we're simply waiting for that opinion to come out. Yeah, at present, there really isn't anything more we can share, since no deadlines have been established.

Operator

operator
#60

Mr. Parekh, have you gotten through all your questions?

Keyur Parekh

analyst
#61

Yes, go ahead. Thanks.

Operator

operator
#62

Our next question comes from Falko Friedrichs at Deutsche Bank. Your line is open.

Falko Friedrichs

analyst
#63

Thanks. I have two questions, please. First, on Xarelto — it fell 5% in Q1. How much of that really came from China? Or to put it another way, how would it have done in Q1 without that China headwind? My second question is about your soybean business: do you feel you're catching up in the market again and gaining share again, or is it still too early? Thank you.

Werner Baumann

executive
#64

Hey, Falko. I'll do my best to answer that. In Q1, Xarelto posted positive growth in every one of our regions except China. In China, our sales were cut roughly in half — 50% — reflecting both price and volume effects in Q1 stemming from VBP. Europe continued to grow strongly. Japan was roughly flat versus the prior year. That's where things stand.

Rodrigo Santos

executive
#65

Let me move to the second part of your question, which concerns market share in Crop Science. Having worked in this market for so many years, I'm typically very careful about market share figures in Q1 — particularly since, in the U.S., we're only at the beginning of planting. To give you one data point: I was checking on Sunday. Planting in the U.S. is quite late, correct? Corn planting stood at 22% over the weekend, whereas a normal five-year average would be 50%, and for soybean it's 12%, versus a typical five-year average of 24%. We are behind. It's difficult to put an exact figure on market share. What I can say is that we observe — and we've projected for this year — that we will be the leading platform in soybean, and I believe we'll be the leading platform in the industry in the U.S., and that's what our numbers are showing as well. I'll share more detail on market share in Q2, once we have more of the planting and the data firmed up, but we remain very much in line with the plans we set for the year for soybean.

Wolfgang Nickl

executive
#66

Thanks. What are the particular factors behind the somewhat later planting this year?

Rodrigo Santos

executive
#67

This is tied to the weather, correct? Some areas have cold conditions, and there's dry weather too. That creates a slight delay. That's roughly the shift we're observing with soy and corn, as was announced. The move of 2 to 4 million acres from corn to soy is connected to that as well. At the end of the day, we'll have to see how that plays out. Thank you.

Wolfgang Nickl

executive
#68

All right, thanks.

Operator

operator
#69

Moving on to Joel Jackson at BMO Capital Markets, your line is open.

Alex Chen

analyst
#70

Hello, Alex Chen here, filling in for Joel Jackson. I appreciate you taking my questions. As my first question, could you perhaps discuss the difficulties, if there are any, of passing inflation through into crop chemicals pricing, and how that might vary between glyphosate and non-glyphosate products? As my second question, maybe you could give us some detail on sales to Ukraine up to now, and what your projections are, or how much of Ukraine's acreage has been planted or will be planted? Thank you.

Rodrigo Santos

executive
#71

Let me walk you through it. So for the full year, as we said, we had projected a price increase of 6%-7% on corn fungicide and insecticides overall, and we're delivering above inflation on that, which lets us generate the growth we set out to achieve. I want to underscore a few of the figures Wolfgang referenced. In Q1, fungicide rose 19%, insecticides 12%, and corn 10%, driven mostly by pricing, and we're capturing that thanks to the value of the technology innovation we're bringing. That's the key value driver here — the innovation and technology we're launching into the market. We're seeing it. It also shows up when I look at our plans for the years ahead and the reach of the pipeline we have, which we just announced this year. This is the year we announced the most prolific pipeline we've had in many years. We're seeing a great deal of the Precision Breeding work we're doing on soybean, corn, and cotton as well. We're also seeing new biotech launches. That covers that piece. Just one piece of information on Ukraine, and then I'll hand over to Werner to add to it.

Rodrigo Santos

executive
#72

In Crop Science, we're seeing roughly 75% of the crop in Ukraine being planted by farmers. Werner?

Werner Baumann

executive
#73

Thanks, Rodrigo. Let me just add a couple of points here. Beyond crop, you've probably also noticed in consumer that we've pushed through strong pricing. Yeah. As far as we can, we're passing along inflation through the prices we're implementing. On top of that, for Q1, we haven't observed anything material in our numbers stemming from Ukraine and, in fact, from Russia as well. Yeah. As you know, the Ukrainian business is largely, as Rodrigo said, an ag business, with more than two-thirds being ag. You know, we have been — and I think not just us, but every company operating in the ag inputs space — going out of our way to ensure they can supply, and quite a bit of planting has actually taken place. Yeah. Which, I think, given the circumstances, is good news.

Operator

operator
#74

Mr. Jackson, have you gotten through all your questions?

Alex Chen

analyst
#75

Yes, thanks.

Operator

operator
#76

Our next question comes from Christian Faitz at Kepler Cheuvreux. Please proceed.

Christian Faitz

analyst
#77

Yes, thanks. Good afternoon, gentlemen, and congratulations on the results. This question is for Wolfgang. You brought up EUR 200 million of cost inflation in Crop Science for Q1. Roughly what did cost inflation come to in the other two segments? Is it reasonable to expect similar cost effects in Q2, with that year-on-year effect tapering off in Q3 and Q4 assuming input prices stay where they are? And my second question: judging from what you can see at this point, is there any impact on your activities from the lockdowns currently happening in China? Thank you.

Wolfgang Nickl

executive
#78

Thank you. I'll keep my response fairly high-level, since we don't want to split this out across every segment. Crop Science is where we did it, because that business carries by far the largest COGS share. As Werner mentioned, inflation is present across the board. It's one of those macro trends. You see it in energy, in freight, and in active ingredients. Labor is affected as well. The task is essentially to pass those costs through to the market. That's going reasonably well in Crop Science and Consumer Health. Pharma is somewhat harder, since most of it is pre-negotiated there. I'll leave it to my colleagues to speak about China, probably. Or Werner, perhaps you could take a first stab at it, and cover the effects there.

Werner Baumann

executive
#79

Yeah. Hi, Christian. Regarding China, Q1 had almost no effect, though more is building. China is obviously being hit by the lockdowns. We see that in our consumer business, and in our pharma business as well. How much this will affect our numbers is far too early to say, since there's no clear view of how long the lockdowns will last and how severe they'll be. Yeah. As things stand, I think everything is in place as far as our outlook for the year goes.

Christian Faitz

analyst
#80

Alright, that's great. Thank you — that's quite helpful.

Operator

operator
#81

And our next question comes from Steve Byrne at Bank of America. Please go ahead.

Steve Byrne

analyst
#82

Yeah. Thanks. Rodrigo, a few ag channel checks told us you were selling some Enlist soybeans this year. Could you move that way, or is it only certain geographies, or would you call it sort of testing the waters before your own next-generation herbicide-tolerant stack that's going to include 2,4-D tolerance? When might that happen?

Werner Baumann

executive
#83

It's really difficult to make out. Do you have a headset or something like that? Is there any way to make it better? Because we struggled to catch that question.

Steve Byrne

analyst
#84

Perhaps this would be useful.

Werner Baumann

executive
#85

Yeah, slightly improved.

Steve Byrne

analyst
#86

Is this coming through clearly at your end?

Werner Baumann

executive
#87

Sure, let's give that a try.

Steve Byrne

analyst
#88

Okay, so my question was directed at Rodrigo, and it concerned a few channel check remarks indicating that Bayer had been selling certain Enlist soybeans during this year. I'm not sure whether that amounts to simply testing the waters before your upcoming soybean stack, which is going to carry 2,4-D tolerance. At what point do you expect that to become available?

Rodrigo Santos

executive
#89

Allow me to speak briefly about the platforms we have in soybean. That is an excellent question regarding our soybeans. A significant transition is underway, and that is the price effect we observed in Q1 for XtendFlex. That represents the first migration we are seeing. We have HT4, which you mentioned, and we intend to launch it by 2027, 2026, 2027, depending on the regulatory scheme, correct? We are keeping track of that one. What we have today is the migration for XtendFlex. Xtend will remain our primary platform. As we also said earlier, we're going to have Enlist in certain specific situations in markets, but we are planning the full launch of HT4, where we're going to have our own two, 4-D resistance down the road, and that is a very strong platform, and it will be a major breakthrough in the market as well.

Steve Byrne

analyst
#90

Rodrigo, I’ve got one follow-up on the Intacta2 launch in South America. I realize harvest is still going on, but do you have any observations about how Intacta2 performed versus Intacta1 on yield and, perhaps more significantly, on the need for insect protection applications—how did those two compare? Has anything shifted in your expectations for that ramp?

Rodrigo Santos

executive
#91

Thank you for raising that. It's an excellent question. Intacta2 Xtend has us really enthusiastic. Three weeks back I was in Brazil, in Mato Grosso, meeting with some growers, and seeing part of the performance was truly remarkable. You put your finger on it, exactly. The yield results we're observing are strong. A yield gain is showing up. For farmers, that's the number one reason to pick this technology. On top of that, we're seeing wider-spectrum worm control as well. It's coming in a bit above our expectations, and in Brazil a substantial move from Intacta over to Intacta2 Xtend is underway. Things are going extremely well up to now. Naturally, harvest is still ongoing and we'll learn more, but it's progressing very nicely.

Steve Byrne

analyst
#92

What steps do you take to stop those seeds from ending up in Argentina through illegal channels?

Rodrigo Santos

executive
#93

Okay, so there are a few different actions at play here. First off, Argentina has no regulatory requirement, correct? Unlike in the past, you don't need any approval to plant in that country. Argentina doesn't have a regulatory approval process. Beyond that, there are other steps you can pursue — legal actions, and also things related to agreements already in place. The main point is that there's a regulatory situation, and there's no breeding effort under way in Argentina. No varieties are being developed for Argentina either. That's. There are a number of elements to this, but I'd say we feel confident that — unlike what we probably saw with the first generation many years back — in this instance we now have all the patent protection. There are no breeding efforts for Argentina today, and there are no regulatory approvals either.

Steve Byrne

analyst
#94

I appreciate that.

Rodrigo Santos

executive
#95

I appreciate that.

Operator

operator
#96

Richard Vosser from JP Morgan has the next question. Go right ahead.

Richard Vosser

analyst
#97

Hello there. Apologies — pardon me. Hi, and thank you for the opportunity to ask. To begin, I want to build on what Sachin asked. It appears to me that among the strategic gaps you cited in pharma was the absence of a credible, robust U.S. presence, along with the effort to build one. Kerendia is how you've been pursuing that. I'd like a quick clarification regarding what was said about Factor XI, since owning that would appear to place you squarely in the top tier when it comes to a U.S. business, and your remarks about partnering kept that possibility open. That would appear to tackle several of the strategic concerns. I'd just like your perspective on that. And then, second, on ag. It's likely somewhat soon, but should we be expecting anything on currency conditions? You brought up weather causing planting to run late, yet on pricing for the coming year with respect to the North American season — clearly we've seen price cards go up during this year, and in August you'll get another opportunity to consider it. Given rising input costs, should we expect prices to be increased once more for 2023? Thank you very much.

Rodrigo Santos

executive
#98

Hey Richard, and thanks for matching our excitement about asundexian and about how strong our U.S. position is. Yes, we're gearing up for success in the U.S., and yes, we're prepared to handle this ourselves.

Oliver Maier

executive
#99

I just mentioned that I don’t want to rule anything out while we have it as an option. Let’s wait and see what happens with our phase III program, but we are prepared to handle this on our own.

Rodrigo Santos

executive
#100

Richard, allow me to address the second item as well. Many thanks for raising it. Let me offer a bit of perspective on this. That is an excellent question. I have spent 25 years working in this innovation industry. Let me share one point. Whenever we plan prices, the first thing we notice when we examine an innovation closely, such as our engine here, is our performance. The performance of our technology, our innovation, and what I am seeing excites me very much. That is something important. We announced that we launched 500 new varieties and hybrids stemming from the Precision Breeding that we established. We are launching SmartStax PRO in U.S., VT Pro4 in South America. We just discussed Intacta2 Xtend and XtendFlex, and we have TriVolt launch in cotton. In short, when I look at our plans for 2023, I am confident. It is early to say what the price cards would be for that next year. Of course, that is a very important element when we consider the guidance we set for the EBITDA margin over the next years will be the pricing. I think we have a good engine in terms of innovation. We have good discipline on pricing, so I feel confident about the plans that we're gonna probably launch by June, July, as you mentioned.

Rodrigo Santos

executive
#101

I realize it's premature right now to discuss 2023 and 2024, though the fundamentals remain very strong. That's how I'd put it. Thanks so much.

Operator

operator
#102

Vosser, have you gotten through all your questions?

Richard Vosser

analyst
#103

That's right — thanks so much. That's really kind of you.

Operator

operator
#104

Ladies and gentlemen, we ask for your understanding that time constraints mean we need to end this call at this point. Apologies, Mr. Maier. Kindly go ahead with any further points you would like to bring up again.

Oliver Maier

executive
#105

Thanks so much, Stuart. I appreciate everyone giving us your time and attention today, and the excellent questions — really appreciated. That wraps up our call for Q1, and we'll talk soon. Thank you. Stay safe.

Operator

operator
#106

Ladies and gentlemen, that brings us to the end of Bayer AG's Q1 2022 conference call for investors and analysts. We appreciate your joining us. You are now free to disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.